TRAVERE THERAPEUTICS, INC. Restructuring and Related Cost, Cost Incurred to Date
TRAVERE THERAPEUTICS, INC. (TVTX) had Restructuring and Related Cost, Cost Incurred to Date of $13.80 million as of 2024-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Restructuring and Related Activities
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2026-02-19
- 2024-12-31: Restructuring and Related Cost, Cost Incurred to Date $13.80M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2024-12-31 | $13.80M 10-K · filed 2026-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |